The interaction between calcium channel blockers, particularly verapamil, and inhalational anesthetics such as halothane, enflurane, and isoflurane can lead to significant hemodynamic effects, primarily due to the combined negative inotropic properties. These interactions are especially concerning because they can depress cardiac contractility, reduce vascular resistance, and ultimately cause profound cardiovascular depression, especially in patients with pre-existing cardiac conditions.
A notable study of eight patients undergoing coronary artery bypass surgery revealed that the use of halothane anesthesia combined with intravenous verapamil (0.15 mg/kg over 10 minutes) significantly decreased mean arterial pressure (MAP), cardiac index, and left ventricular contractility. Halothane alone caused a substantial reduction in MAP and impaired left ventricular function, but the addition of verapamil further exacerbated this effect, resulting in a 16% additional reduction in left ventricular peak positive dP/dT, which is a key measure of myocardial contractility. Furthermore, verapamil caused a 12% additional reduction in MAP due to systemic vasodilation, demonstrating its potent vasodilatory effects when combined with halothane.
Interestingly, although this study showed significant cardiovascular depression, the patients, all of whom had normal resting left ventricular function and were on chronic low-dose beta-blocker therapy, did not experience overt adverse effects such as arrhythmias or myocardial ischemia. However, this should not obscure the potential risk for serious complications, particularly in patients with underlying myocardial impairment or compromised cardiovascular reserve. The combined hypotensive and negative inotropic effects of CCBs and inhalational anesthetics like halothane can precipitate myocardial ischemia or heart failure in more vulnerable patients. This highlights the need for dose titration and vigilant hemodynamic monitoring when CCBs and inhalational anesthetics are used concurrently.
Most of this literature dates from the 1980s and studied halothane and enflurane, neither of which is used in the United States today. Isoflurane, sevoflurane, and desflurane share the same direction of interaction, additive dose-dependent myocardial depression and vasodilation, but to a more modest degree, and a patient continued on an oral CCB through surgery rarely has a problem with a volatile anesthetic titrated to effect. The combination that does produce trouble is additive nodal depression: a non-dihydropyridine (verapamil or diltiazem) plus a beta-blocker plus a volatile anesthetic can produce sinus bradycardia, junctional rhythm, or atrioventricular block, and a vagal surgical stimulus, neostigmine, dexmedetomidine, or an opioid bolus can unmask it. Dihydropyridines (amlodipine, nifedipine, nicardipine, clevidipine) have little effect on conduction, so with them the interaction is largely one of vasodilation.
Effects on Arterial Pressure and Systemic Vascular Resistance (SVR)
CCBs, when combined with halogenated anesthetics, tend to lower mean arterial pressure, but the two drug classes get there by different routes. Halothane lowers pressure mainly by depressing cardiac output, with little net change in systemic vascular resistance (SVR); enflurane depresses cardiac output and lowers SVR modestly; isoflurane, like sevoflurane and desflurane, lowers pressure mainly by reducing SVR while cardiac output is relatively preserved. A CCB adds its own arteriolar dilation (every CCB) and, for verapamil and diltiazem, further negative inotropy. In the coronary bypass study above, verapamil's additional 12% fall in MAP was due to systemic vasodilation with no change in heart rate, and in halothane-anesthetized dogs cumulative verapamil lowered SVR by as much as 51% while mean arterial pressure fell 37%. Results vary with the model: in one swine study only nifedipine lowered SVR when added to halothane. Because the volatile anesthetic also blunts the baroreflex, the reflex tachycardia that normally offsets CCB vasodilation in the awake patient is attenuated under anesthesia.
Coronary Blood Flow (CBF)
The combination of CCBs and halogenated anesthetics can modulate coronary blood flow (CBF) through two mechanisms: decreasing coronary perfusion pressure and causing coronary artery vasodilation. While many studies report no significant change in CBF despite a reduction in perfusion pressure, some experimental models, such as open-chest sheep, have shown a dramatic decrease in CBF when verapamil is combined with halothane. In contrast, the combination of nicardipine and isoflurane resulted in increased CBF despite a substantial reduction in arterial pressure.
Conduction System Effects
CCBs and halogenated anesthetics also exert additive effects on the cardiac conduction system, particularly on atrioventricular (AV) conduction and ventricular conduction. Halothane and enflurane slow AH conduction, while all three halogenated anesthetics (halothane, enflurane, isoflurane) slow HV conduction. The addition of CCBs, especially verapamil, can exacerbate these effects, leading to prolonged AH intervals and even sinus arrest. In some cases, these combinations have resulted in atrioventricular block and complete heart block, particularly with enflurane and halothane. However, verapamil and diltiazem can provide protection against epinephrine-induced arrhythmias in patients anesthetized with halothane.
Renal and Carotid Blood Flow
The combination of CCBs and halogenated anesthetics can worsen reductions in renal and carotid blood flow that are already seen with the use of halogenated anesthetics alone. This has been demonstrated with combinations like nicardipine with isoflurane and verapamil with halothane. In the pulmonary circulation, verapamil in combination with halothane or isoflurane can inhibit hypoxic pulmonary vasoconstriction, which may affect oxygenation during anesthesia.
Pharmacodynamic and Pharmacokinetic Interactions
Pharmacodynamic and pharmacokinetic interactions between CCBs and halogenated anesthetics are significant. Halothane and enflurane act similarly on calcium channels in myocardial cells, while isoflurane exhibits distinct effects. Halothane reduces calcium release from the sarcoplasmic reticulum, which amplifies the negative inotropic effects of CCBs. Additionally, halogenated anesthetics impair baroreflex responses, reducing the sympathetic compensatory response to the hypotensive effects of CCBs. Pharmacokinetically, studies have demonstrated that serum verapamil levels increase when used with halothane, enflurane, or isoflurane. In chronically instrumented dogs, each of the three agents cut verapamil's total clearance by roughly 40% (from 64 to 37-41 L/h) and shrank its volume of distribution. Verapamil is a high-extraction drug, so the reduction in hepatic blood flow produced by the volatile anesthetic lowers its clearance, and slower tissue distribution keeps more drug in the plasma; both heighten the cardiovascular effects of the combination, which is one reason intravenous verapamil given during a volatile anesthetic behaves like a larger dose.
Reversal of Negative Inotropic Effects
The negative inotropic effects induced by CCBs combined with halogenated anesthetics can often be reversed by the administration of calcium: calcium chloride 10% 10 mL (1 g) through a central line, or calcium gluconate 10% 30 mL (3 g) peripherally, repeated as needed while ionized calcium is followed. Calcium does less for the vasodilatory component, which is treated by lightening the volatile anesthetic and giving a vasopressor (phenylephrine for pure vasodilation, norepinephrine or epinephrine when contractility is also down). Conduction disturbances may require atropine, isoproterenol (isoprenaline), glucagon, or temporary pacing. When the picture is overdose-level, as with an intravenous CCB given on top of a chronic oral agent, management follows the CCB poisoning consensus: calcium, high-dose insulin (regular insulin 1 unit/kg as a bolus and 1 unit/kg per hour with dextrose and potassium replacement), norepinephrine or epinephrine, and lipid emulsion or mechanical support if refractory. These strategies address the additive depressive effects on cardiac function.
Clinical Implications and Safety Concerns
There are limited clinical studies that address the safety of combining CCBs and halogenated anesthetics. However, some reports highlight the risks, particularly with the IV administration of verapamil during anesthesia. For example, cases of cardiac arrest have been reported when verapamil was administered with halothane in patients with cardiovascular instability. Conversely, the combination of nicardipine with halothane appears to be safer. In clinical practice, preoperative CCB therapy is generally considered safe to continue, and standard practice is to continue it through the morning of surgery; the 2024 AHA/ACC perioperative guideline specifically recommends continuing a non-dihydropyridine in hypertrophic cardiomyopathy and otherwise gives no reason to hold the class, while stopping it offers no benefit and risks loss of blood pressure or rate control. Caution is advised when administering IV CCBs during halogenated anesthesia due to the potential for significant cardiovascular depression and conduction abnormalities. For intraoperative hypertension, the dihydropyridines nicardipine and clevidipine are the intravenous CCBs of choice because they lower SVR with little effect on contractility or conduction; in the ECLIPSE trials clevidipine controlled blood pressure at least as well as nitroglycerin or nitroprusside with no difference in mortality. For a regular narrow-complex supraventricular tachycardia under anesthesia, adenosine is first line; if verapamil is used, it is given in small increments (2.5 mg) with the volatile anesthetic reduced and a vasopressor and calcium at hand.
| System | Effect of the combination |
|---|---|
| Arterial pressure | Mean arterial pressure falls; with halothane plus IV verapamil 0.15 mg/kg, a 12% additional reduction in MAP from systemic vasodilation. |
| Contractility | Additive negative inotropy; verapamil added to halothane produced a 16% additional reduction in left ventricular peak positive dP/dT. |
| Systemic vascular resistance | Halothane lowers pressure mainly through cardiac output with little net SVR change; enflurane lowers SVR modestly; isoflurane, sevoflurane, and desflurane lower SVR most. Every CCB adds arteriolar dilation (verapamil lowered SVR up to 51% in halothane-anesthetized dogs), and the volatile blunts the baroreflex that would otherwise compensate. |
| Coronary blood flow | Usually unchanged despite lower perfusion pressure; verapamil with halothane fell sharply in open-chest sheep, while nicardipine with isoflurane increased CBF. |
| Conduction | Halothane and enflurane slow AH conduction and all three volatiles slow HV conduction; adding verapamil can prolong AH intervals and cause sinus arrest; AV block and complete heart block have been reported, particularly with enflurane and halothane. |
| Renal and carotid flow | Reductions already seen with volatiles alone are worsened (nicardipine with isoflurane, verapamil with halothane). |
| Pulmonary circulation | Verapamil with halothane or isoflurane inhibits hypoxic pulmonary vasoconstriction, which may affect oxygenation. |
| Drug levels | Serum verapamil rises with halothane, enflurane, or isoflurane, possibly from reduced hepatic blood flow or autonomic dysfunction. |
